HL60型
细胞分化
维甲酸
分化疗法
急性早幼粒细胞白血病
维甲酸
白血病
细胞培养
癌症研究
药理学
化学
效力
细胞生物学
生物
免疫学
体外
生物化学
遗传学
基因
作者
Cong Wang,Qun Zhang,Bao-Di Gou,Tian‐Lan Zhang,Kui Wang
标识
DOI:10.1016/j.biopha.2014.05.001
摘要
Differentiation therapy in the treatment of leukemia is often hampered by limitations on using certain pharmaceutical regents or on the required doses due to various reasons, such as drug-resistance and retinoic acid syndrome. To circumvent these problems, a strategy might be developed on the basis of the ability of drug-differentiated cells to stimulate differentiation in leukemia cells. Using the promyelocytic leukemia cell line HL60 as a cell model, we assessed the differentiation-stimulating potency of differentiated granulocytes and monocytes/macrophages after treatments with all-trans retinoic acid (ATRA) and 12-O-tetradecanoylphorbol-13-acetate (TPA), respectively. ATRA- and TPA-differentiated cells were able to stimulate differentiation in fresh HL60 cells, accompanied by inhibition on cell growth to various extents. The differentiated cells of the second generation, especially those originated from TPA treatment, were as potent as the drugs themselves in stimulating differentiation in fresh HL60 cells. On the basis of “differentiation induced by differentiated cells”, we explored the feasibility of ex vivo therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI